These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections. Heo YA Drugs; 2021 Feb; 81(3):377-388. PubMed ID: 33630278 [TBL] [Abstract][Full Text] [Related]
9. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684 [TBL] [Abstract][Full Text] [Related]
10. [Imipenem-cilastatin-relebactam used to treat ventilator-associated pneumonia developing after infection with SARS-CoV-2]. Zahornacký O; Porubčin Š; Rovňáková A; Jarčuška P Klin Mikrobiol Infekc Lek; 2022 Mar; 28(1):18-21. PubMed ID: 36183413 [TBL] [Abstract][Full Text] [Related]
11. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
12. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. Sims M; Mariyanovski V; McLeroth P; Akers W; Lee YC; Brown ML; Du J; Pedley A; Kartsonis NA; Paschke A J Antimicrob Chemother; 2017 Sep; 72(9):2616-2626. PubMed ID: 28575389 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia. Naik J; Dillon R; Massello M; Ralph L; Yang Z J Comp Eff Res; 2023 Mar; 12(3):e220113. PubMed ID: 36688591 [No Abstract] [Full Text] [Related]
14. Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance. Werarak P; Kiratisin P; Thamlikitkul V J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S126-38. PubMed ID: 20364567 [TBL] [Abstract][Full Text] [Related]
15. Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program. Lob SH; Hackel MA; Kazmierczak KM; Hoban DJ; Young K; Motyl MR; Karlowsky JA; Sahm DF Diagn Microbiol Infect Dis; 2017 Jun; 88(2):171-176. PubMed ID: 28291628 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram-Negative Bacterial Infections: A Phase 1b, Open-Label, Single-Dose Clinical Trial. Bradley JS; Makieieva N; Tøndel C; Roilides E; Kelly MS; Patel M; Vaddady P; Maniar A; Zhang Y; Paschke A; Chen LF J Clin Pharmacol; 2023 Dec; 63(12):1387-1397. PubMed ID: 37562063 [TBL] [Abstract][Full Text] [Related]
17. A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants. Wang X; Liu N; Wei Y; Zhang S; Li H; Yan B; Patel M; Wang H; Boundy KE; Colon-Gonzalez F; Zang Y; Zhao X Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33288637 [TBL] [Abstract][Full Text] [Related]
18. In-vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015-2017. Karlowsky JA; Lob SH; Kazmierczak KM; Young K; Motyl MR; Sahm DF Int J Antimicrob Agents; 2020 Jan; 55(1):105841. PubMed ID: 31704217 [TBL] [Abstract][Full Text] [Related]
19. New Antibiotics for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia. Bassetti M; Mularoni A; Giacobbe DR; Castaldo N; Vena A Semin Respir Crit Care Med; 2022 Apr; 43(2):280-294. PubMed ID: 35088403 [TBL] [Abstract][Full Text] [Related]
20. Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections. Kaye KS; Boucher HW; Brown ML; Aggrey A; Khan I; Joeng HK; Tipping RW; Du J; Young K; Butterton JR; Paschke A Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094127 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]